EGFR与C－erbB－2癌基因蛋白在甲状腺乳头状腺癌中的表达  

Expression of EGFR and C-erbB-2 Oncoproteins in Thyroid Carcinoma

作　　者：许良中[1] 郑颂国[1] 朱伟萍[1] 张秦明[1] 

机构地区：[1]上海医科大学肿瘤医院

出　　处：《实用癌症杂志》1995年第2期102-104,共3页The Practical Journal of Cancer

摘　　要：本文作者研究了上皮生长因子受体（ＥＧＦＲ）和Ｃ－ｅｒｂＢ－２癌基因蛋白在５０例甲状腺癌和６６例甲状腺良性疾患中的表达。５０例甲状腺癌中，ＥＧＦＲ阳性者２６例（５２％），Ｃ－ｅｒｂＢ－２阳性者２５例（５０％）。ＥＧＦＲ和ｃ－ｅｒｂＢ－２共同表达阳性者的淋巴结转移率（９２．８５％）明显高于两者共同表达阴性者（６１．５３％）（Ｐ＜０．０５）。ＥＧＦＲ阳性者ＡｇＮＯＲ数（２．５９±０．６４／核）也明显高于ＥＧＦＲ阴性者（１．３９±０．１８／核）（Ｐ＜０．００１）。ＥＧＦＲ与Ｃ－ｅｒｂＢ－２共同表达阳性，同时ＡｇＮＯＲ计数高的甲状腺癌具有较高的恶性度。因此，对这种病人要予以特别的治疗措施并抓紧随访工作。The expression of EGFR and C-erbB-2 oncoproteins in 50 cases of thyroid carcinoma and 66 cases ofthyroid benign disease have been studied. Among 50 cases of thyroid carcinoma, positive staining was found in 26cases(52%)for EGFR,25 cases(50%)for C-erbB-2。 The metastatic rate of lymph nodes in EGFR(+),C-erbB-2(+)Group(92. 85%)was significantly higher than that of EGF(一), C-erbB-2(一)group(6l. 53%)(P<0.05). The number of AgNORs in EGFR(+)group(2。 59±0. 64/nucleus)was also significantly higher than thatof EGFR(一)group(1. 39±0.18/nucleus)( P<0. 001).Thyroid carcinomas with expression of EGFR(+),C-erbB-2 (+)and simultaneously with high number of AgNORs are more likely to have a higher malignancy。Therefore ,special therapeutic measures and close follow-up are appropriate for these patients.

关 键 词：甲状腺肿瘤 乳头状腺癌 EGFR 癌基因蛋白 

分 类 号：R736.102[医药卫生—肿瘤]